Core C The cell culture will provide cell culture support for this Program Project. The assays we use can detect hematopoietic progenitors at various stages of differentiation and can distinguish between normal and leukemic colony-forming cells. These assays are well suited to address a major issue arising in this Program Project, namely the derivation ofthe cells responding to various anti-leukemic agents investigated in this P01. These assays will be used to investigate the role of extrinsic cytokines including granulocytemacrophage colony stimulating factor (GM-CSF) and c-Kit ligand in protecting CML progenitors from Imatinib (IM;Gleevec)-induces apoptosis using blood and marrow cells of both patients sensitive and resistant to Gleevec. These studies will be conducted in collaboration with Projects 4 and 5. Also, we will provide support to Project 5 in studying the effects of lipocalin and antisense 24p3 and BCR on Ph+ cell lines and on normal and brc-abl+ eariy and mature progenitors. In collaboration with Project 3 we will study whether disruption ofthe microenvironment-dedicated protection of CML progenitors will affect the sensitivity of CML colony-forming cells to protein kinase inhibitors and whether Bcl-2 inhibitors will potentiate the effects of protein kinase inhibitors. Thus, the Specific Aims are the following: 1) To investigate whether extrinsic stimulatory cytokines protect CML progenitors from apoptotic effect of IM and other protein kinase inhibitors in collaboration with Drs. Deininger (Project 4) and Arlinghaus (Project 5) 2) To study the effects of anti-24p3 and anti-NGAL antibodies and BCR (transduced by the lentivirus vector infection system) on CML cell lines and fresh CML and normal marrow cells in collaboration with Dr. Arlinghaus (Project 5). 3) To investigate how interruption ofthe interaction between the hematopoietic stroma and the CML clone would affect the sensitivity of normal and BCR-ABL+ progenitors to protein tyrosine kinase inhibitors. We will study the effect of agents that interrupt the interaction between SDF-1 and CXCR4, and the combination of tyrosine kinases and Bcl-2 inhibitors using a combination of hematopoietic stroma cultures, the long-term culture initiating cell (LTCIC) assay and donogenic assays, in collaboration with Dr. Andreeff (Project 3).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-23
Application #
8513794
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$170,815
Indirect Cost
$103,640
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Qazilbash, M H; Wieder, E; Thall, P F et al. (2016) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia :
Jain, Preetesh; Kantarjian, Hagop; Sasaki, Koji et al. (2016) Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173:114-26
Tripathi, Satyendra C; Peters, Haley L; Taguchi, Ayumu et al. (2016) Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113:E1555-64
Andreeff, Michael; Kelly, Kevin R; Yee, Karen et al. (2016) Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 22:868-76
Jain, Preetesh; Kantarjian, Hagop; Patel, Keyur P et al. (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269-75
Chen, Z; Cortes, J E; Jorgensen, J L et al. (2016) Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30:1606-9
Hoehn, Daniela; Cortes, Jorge E; Medeiros, L Jeffrey et al. (2016) Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S86-92
Lee, Dean A; Denman, Cecele J; Rondon, Gabriela et al. (2016) Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 22:1290-8
Cortes, Jorge E; Lipton, Jeffrey H; Miller, Carole B et al. (2016) Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk 16:286-96
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279

Showing the most recent 10 out of 325 publications